Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Perspective

COVID19 - Far from Over: Call for Urgent Novel and Advanced Measures

Author(s): Abhigyan Choudhury and Suprabhat Mukherjee*

Volume 3, Issue 2, 2022

Published on: 29 November, 2021

Article ID: e280122197574 Pages: 4

DOI: 10.2174/2666796702666211102111805

Abstract

The COVID19 pandemic that started in late 2019 has already killed millions people, it is yet far from over and the road to the COVID-free world is much tougher than we all imagined; however, it ends at a vaccine functional against all coronaviruses. In this article, we try to present the aetiology behind evolution of superior pathogenicity of SARS-CoV-2 and point out fundamental and highly hazardous loopholes in the current vaccination regimens and propose new vaccination strategies. We also suggest societal and personal level management that are necessary to ensure prevention and better recovery outcomes until the arrival of the vaccine. In turn, we apprise the physician for long-term and stringent management of certain chronic diseases, avoiding prescribing certain drugs and suggesting physical exercises and diets that are fortified with specific micronutrients.

Keywords: COVID19, vaccine, diet, drugs, coronaviruses, universal-vaccine, nutrition.

Graphical Abstract

[1]
WHO Coronavirus (COVID-19) Dashboard. Available from: https://covid19.who.int
[2]
Nakagawa S, Miyazawa T. Genome evolution of SARS-CoV-2 and its virological characteristics. Inflamm Regen 2020; 40(1): 17.
[http://dx.doi.org/10.1186/s41232-020-00126-7] [PMID: 32834891]
[3]
Tadić B, Melnik R. Modeling latent infection transmissions through biosocial stochastic dynamics. PLoS One 2020; 15(10): e0241163.
[http://dx.doi.org/10.1371/journal.pone.0241163] [PMID: 33095815]
[4]
Ulloa S, Bravo C, Ramirez E, Fasce R, Fernandez J. Inactivation of SARS-CoV-2 isolates from lineages B.1.1.7 (Alpha), P.1 (Gamma) and B.1.110 by heating and UV irradiation. J Virol Methods 2021; 295: 114216-6.
[http://dx.doi.org/10.1016/j.jviromet.2021.114216] [PMID: 34171342]
[5]
COVID-19 Vaccine Breakthrough Infections Reported to CDC - United States, January 1-April 30, 2021 MMWR Morb Mortal Wkly Rep 2021; 70(21): 792-3.
[PMID: 34043615]
[6]
Choudhury A, Mukherjee G, Mukherjee S. Chemotherapy vs. Immunotherapy in Combating NCOVID19: An Update. Hum Immunol 2021.
[http://dx.doi.org/10.1016/j.humimm.2021.05.001]
[7]
Kulkarni R. Antibody-dependent enhancement of viral infections. Dynamics of immune activation in viral diseases 2019; 9-41.
[http://dx.doi.org/10.1007/978-981-15-1045-8_2]
[8]
Coronavirus (COVID-19) Vaccinations - Statistics and Research - Our World in Data. Available from: https://ourworldindata.org/covid-vaccinations
[9]
Wang W, Wu Q, Yang J, et al. Global, regional, and national estimates of target population sizes for COVID-19 vaccination. medRxiv 2020; 2020.09.29.20200469.
[http://dx.doi.org/10.1101/2020.09.29.20200469]
[10]
Choudhury A, Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. J Med Virol 2020; 92(10): 2105-13.
[http://dx.doi.org/10.1002/jmv.25987] [PMID: 32383269]
[11]
Choudhury A, Das NC, Patra R, Mukherjee S. In silico analyses on the comparative sensing of SARS-CoV-2 mRNA by the intracellular TLRs of humans. J Med Virol 2021; 93(4): 2476-86.
[http://dx.doi.org/10.1002/jmv.26776] [PMID: 33404091]
[12]
Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol 2020; 92(5): 491-4.
[http://dx.doi.org/10.1002/jmv.25709] [PMID: 32056249]
[13]
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging (Albany NY) 2020; 12(7): 6049-57.
[http://dx.doi.org/10.18632/aging.103000] [PMID: 32267833]
[14]
Choudhury A, Mukherjee S. Taming the storm in the heart: Exploring different therapeutic choices against myocardial inflammation in COVID-19. Recent Adv in Anti-Infective Drug Discv 2021; 16.
[http://dx.doi.org/10.2174/2772434416666210616124505] [PMID: 34961430]
[15]
Semenzato L, Botton J, Drouin J, et al. Antihypertensive drugs and COVID-19 risk: A cohort study of 2 million hypertensive patients. Hypertension (Dallas, Tex : 1979) 2021; 77(3): 833-42.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.120.16314] [PMID: 33423528] [PMCID: PMC7884243]
[16]
Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring) 2020; 28(6): 1005.
[http://dx.doi.org/10.1002/oby.22818] [PMID: 32237206]
[17]
Rowland SP, O’Brien Bergin E. Screening for low testosterone is needed for early identification and treatment of men at high risk of mortality from Covid-19. Crit Care 2020; 24(1): 367.
[http://dx.doi.org/10.1186/s13054-020-03086-z] [PMID: 32560707]
[18]
Fatima Y, Bucks RS, Mamun AA, et al. Shift work is associated with increased risk of COVID-19: Findings from the UK Biobank cohort. J Sleep Res 2021; 30(5): e13326.
[http://dx.doi.org/10.1111/jsr.13326] [PMID: 33686714]
[19]
Lockyer S. Effects of diets, foods and nutrients on immunity: Implications for COVID-19? Nutr Bull 2020; 45(4): 456-73.
[http://dx.doi.org/10.1111/nbu.12470]
[20]
Yanuck SF, Pizzorno J, Messier H, Fitzgerald KN. Evidence supporting a phased immuno-physiological approach to COVID-19 from prevention through recovery. Integr Med (Encinitas) 2020; 19(Suppl. 1): 8-35.
[PMID: 32425712]

Rights & Permissions Print Cite
Article Metrics
39
2
© 2024 Bentham Science Publishers | Privacy Policy